In an LPS-induced AKI rat model, administration of HIF-1α inhibitors reversed hypoglycemia, normalized enhanced glycolytic activity, and rebalanced inflammatory cytokine profiles (e.g., elevated IL-6/TNF-α and decreased IL-10), indicating that inhibiting excessive HIF-1α activation is a promising therapeutic approach (Yang et al., 2025). The gene discussed is HIF1A; the disease is Hypoglycemia.